XERS Xeris Biopharma Holdings Inc

$XERS And who remembers $1.2 after the Strongbridge acquisition in 2021 When AC and Brodman were all over us.....Bashing! We hung in there for 5 years! For all of those who blocked me, sorry! IDC. Never forget your Princess, We did prevail, and I knew we would. Lot's more to come. In Celebration of the best investment ever ........🧜‍♀️ Let's Freaking go! XERS!🧜‍♀️🧜‍♀️🧜‍♀️

$XERS This is one of the strongest biotechs in a bloody market day, because it is still undervalued. Fair value without even considering XP-8121 right now between $11-$12, everyone can decide what the potential blockbuster XP-8121 is worth to them at the start of phase 3. Swing and accumulate remains our recommendation in this volatile trader's market.

$XERS I bought this stock in early 2024, and I'm so gad I did. Truly found a gem. This is the largest position in my portfolio. If a buyout takes place anywhere between $25-$40, it will be life-changing for myself and my family. Thanks be to God!

$XERS Wow. This is 10x the price a few years ago when Brodman was bashing and some of us were loading up at 1.05. GL longs! You all deserve it! Special thanks to some of the OGs who did so much research and helped me to understand the potential here.

$XERS - many of us have been here a long time - endured those convertibles, the shorts, and the FUD boys - 5 years ago, we would have sold at $6. We have come a long way and are holding strong! We deserve this and are not selling out!

$XERS Times & Perceptions 👁 To be accurate -> Today's revenue-upside thesis is based primarily on assessments published by Xeris management regarding Recorlev and XP-8121. In contrast, the December 30, 2021, assessment was based on the approximate expectations of certain investors. The "problem" today is that very possibly, if we reach ~$60–70 per share by 2030, it could still be far too early to sell. If XP-8121 meets expectations for its target patient population, as the only once-weekly injectable levothyroxine option, it is entirely possible that Xeris could reach a $250-350 valuation per share by 2035, with further growth beyond that... This thing could become a honey trap! Or in other words, you can check out any time you like but you can never leave...

$XERS Wow, a dollar a day. I think a few years ago I dreamed about this and even posted about it. Nice.

$XERS A big bidding war would be nice. $40.00 or more. if any less don't sell. I am good to wait. I have been waiting for 7 years. I can wait a little longer.

$XERS They have to say "we're not for sale", and it means absolutely nothing... They need to float a price before anything becomes real. That's when we will know whether it's a real offer...

$XERS My thoughts re the price increase the last few trading days is that the stock is being accumulated in anticipation of a buyout in the $24 price range.. I see a rapid jump in share price in the coming days. This is time to accumulate a substantial position. There are so many positive catalysts that can propel the stock price into the $20’s.. An easy double here no matter if takeover takes place or not! Bought huge position today..

$XERS We need to hear from our old friend ... You have been away too long, so get out from under your bridge and join the group again... We need to start planning for our Vegas Blowout... 👍

$XERS I am going to make a guess that Amgen would enter the bidding war vs Landbeck. Their offer would most likely be an all cash offer and may be north of $20.00! This is going to be a wild day. waiting for algos and short covering to push this to $12 today .

$XERS “If Xeris continues to reject Lundbeck’s acquisition offers, Lundbeck will probably try to accumulate as many shares as possible on the open market by year-end.

$XERS $20.27 *I’m not posting because there’s nothing to post. Steady growth. Big catalyst incoming. It’s not sexy but I don’t need sexy, I need sustainable returns that beat market baskets.

$XERS Analyst Sentiment ShiftMultiple firms have raised targets recently:Leerink Partners: $12 → $16 (Outperform) Barclays: $9 → $12 (Overweight) Oppenheimer: Reiterated $18 (Outperform) Consensus rating is now Strong Buy, with an average target of $12.29 and a high target of $18 .

$XERS Chicago drugmaker Xeris Biopharma sued Torrent and Rising Pharma groups in New Jersey on Oct 13, alleging their generic dichlorphenamide will infringe newly granted patent 12,758,502 on Keveyis, its primary periodic paralysis drug. Keveyis made $11.7M in Q2 2026, ~13% of $92.1M revenue; market value ~$1.91B at the Oct 12, 2026 close of $10.47. Keveyis made $23.6M in H1 2026, and in August Xeris said a newly allowed patent was expected to protect it to at least 2039. The complaints are allegations; watch for an injunction ruling and Q3 results.

$XERS she is looking good early, but its not how you start the race its how you finish!!!!! LFG, XERS 2 THE MOON!!!!!

$XERS I mentioned a year or 2 back that for long stock holders this is the type of stock they want to be in. Nice growth stock that should grow revenue regardless of the macro environment and perform well. Of course we are a bit more volatile in the short run but as the years go by the growth in EPS and improving story here this is one of the safest bets IMO.

$XERS speaking of good people ... wonder how Sonnier is doing these days? He/she was often a ray of sunshine on an otherwise gloomy day ...

$XERS Actually picked up 500 more shares today. adding to my Collection. Will be continuing to add regularly.. Extremely bullish..